Mana.bio
AI-powered platform for developing lipid nanoparticles for oligonucleotide therapies.
About
Mana.bio is an AI-based drug delivery startup focused on gene therapy, including DNA and RNA-based therapeutics and vaccines. Their technology integrates machine learning and nanotechnology to identify lipid nanoparticle drug delivery systems. They offer ChatLNP, an AI agent named Mina, to help scientists explore literature, predict LNP properties, and optimize formulations. Teams look it up for Life Sciences, Drug Delivery, mRNA.
Frequently asked
What does Mana.bio do?
Mana.bio is a Life Sciences company that offers Software. Teams look it up for Drug Delivery, mRNA, Lipid Nanoparticle (LNP). It is based in Boston, United States and was founded in 2021. Public records show about 20 people and $20M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Mana.bio raised?
Mana.bio has raised a total of $20M in funding. The most recent round on record is Seed.
Where is Mana.bio headquartered?
Mana.bio is headquartered in Boston, United States.
When was Mana.bio founded?
Mana.bio was founded in 2021.
What industry does Mana.bio operate in?
Mana.bio operates in Life Sciences, Drug Delivery, mRNA, Lipid Nanoparticle (LNP), Therapeutics.
How many employees does Mana.bio have?
Mana.bio has approximately 20 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.